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32019-20 Core Recommendation (Unchanged)
 Annual influenza vaccination is recommended for all persons 
aged 6 months and older who do not have contraindications
42019-20 Primary Updates: Vaccine Composition
 Trivalent Vaccines
• A/Brisbane/02/2018 (H1N1)pdm09-like virus—updated
• A/Kansas/14/2017 (H3N2)-like virus—updated*
• B/Colorado/06/2017-like virus (Victoria lineage) 
 Quadrivalent Vaccines
• Above three, plus B/Phuket/3073/2013-like virus (Yamagata lineage)
* Selection of H3N2 component delayed until March 21, 2019
5Projected Influenza Vaccine Supply (2019-20 Season)
Maximum projected supply:     162-169M*
Manufacturer Distribution estimated to begin
AstraZeneca Early September
GSK Mid August
Sanofi Pasteur Late August/Early September
Seqirus Mid August
* Information presented 5/16/19 at the National Adult Immunization and Influenza Summit, 
confirmed June 2019.  The estimate aggregates information across manufacturers about 
potential maximum production for the season and could change based on production yield, 
lot release, and demand for vaccine.
6 Licensure changes for Afluria Quadrivalent and Fluzone Quadrivalent
 Four IIVs expected to be available for ages 6 through 35 months
 Dose volumes differ:
• Fluarix Quadrivalent (IIV4, GSK) 0.5 mL
• FluLaval Quadrivalent (IIV4, ID Biomedical Corp/GSK) 0.5 mL
• Fluzone Quadrivalent (IIV4, Sanofi Pasteur)* 0.25 mL or 0.5 mL
• Afluria Quadrivalent (IIV4, Seqirus)* 0.25 mL
 New table added to Statement summarizing dose volumes
 Dose volume for persons aged ≥3 years is 0.5mL for all IIVs
2019-20 Primary Updates: Licensure Changes 
72019-20 ACIP Guidance Updates:
 Timing of vaccination: 
• Language concerning July/August vaccination moved to top paragraph
“For those requiring only one dose for the season, early vaccination (i.e., in July and August) is likely to be 
associated with suboptimal immunity before the end of the influenza season, particularly among older adults”
 Groups that should be focus of efforts if supply is limited: 
• Language describing health care personnel made consistent with 2011 ACIP Recommendations for the 
Immunization of Health Care Personnel
 Vaccine doses needed for children aged 6 months through 8 years:
• Clarified to indicate that 8-year-olds needing two doses should receive second dose even if they turn 9 
years of age between dose 1 and dose 2 (consistent with AAP guidance)
 Concomitant receipt of two vaccines containing novel adjuvants:
• Notes that given limited safety data, non-adjuvanted influenza vaccines may be considered when giving 
another vaccine containing a novel adjuvant; vaccination should not be delayed if a specific product is 
not available
8For more information, contact CDC
1-800-CDC-INFO (232-4636)
TTY:  1-888-232-6348    www.cdc.gov
The findings and conclusions in this report are those of the authors and do not necessarily represent the 
official position of the Centers for Disease Control and Prevention.
